NCT00360867终止2 期
An Open Label Treatment Extension Study of AMG 706
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Amgen
- 入组人数
- 94
- 主要终点
- Safety (serious adverse events, adverse events, blood pressure and laboratory tests)
研究概览
简要总结
This is an extension study to provide ongoing treatment with AMG 706 monotherapy for subjects with solid tumors who have completed the planned duration of AMG 706 treatment on a separate Amgen protocol and have been evaluated as having stable disease or better. Subjects who are no longer eligible to continue AMG 706 treatment on a separate Amgen protocol (for reasons other than AMG 706 intolerance), but who are receiving clinical benefit or have the potential to receive clinical benefit from AMG 706 per the investigator are also eligible to participate in this trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Women and men 18 yrs or older with solid tumors, previously treated with AMG 706 on an Amgen protocol
- •Subject must meet one of the following criteria: Subject has completed the planned duration of AMG 706 treatment on a separate Amgen protocol and has been evaluated as having stable disease or better or is no longer eligible to continue AMG 706 treatment on separate Amgen protocol for reasons other than AMG 706 intolerance, but is receiving clinical benefit from AMG 706 in the judgement of the investigator.
- •Subject must meet one of the following criteria: Subject has received AMG 706 for at least 8 weeks or until the first protocol-specified tumor evaluation (whichever is longer) or
- •Subject has received at least one dose of AMG 706 but did not receive AMG 706 for =/>8 weeks.
- •Sign informed consent prior to study specific procedures.
排除标准
- •Discontinued from prior AMG 706 study due to AMG 706-related adverse event including intolerance to AMG 706 or for any other reason that a subject's safety could be compromised with continued AMG 706 treatment.
- •Has been off AMG 706 treatment >42 days prior to study day
- •Participating in any intervening investigational device or drug study between previous AMG 706 study and this AMG 706 study or is receiving any other investigational agent(s) other than AMG
- •Uncontrolled hypertension (resting blood pressure > 150/90 mmHg). Anti-hypertensive medications are allowed if the subject is stable on their current dose at time of study day1
- •Requires additional systemic anticancer therapy for primary tumor.
- •ANC < 1.0 x 10^9/L; PLT < 100 x 10^9/L; Hgb < 9 g/dL; serum creatinine > 2.0 mg/dL or calculated clearance < 40 mL/min; AST >2.5 x ULN, or AST =/> to or =/>5.0 x ULN if secondary to liver metastases; ALT >2.5 x ULN or ALT =/>5X ULN if liver metastasis are present; Alkaline phosphates >2.0 x ULN or =/>5 x ULN if liver and bone metastases are present; total bilirubin =/> 2 x ULN (except for subjects with UGT1A1 promoter polymorphism, ie, Gilbert's syndrome. Subjects enrolled with Gilbert's syndrome must have a total bilirubin <3 x ULN).
研究组 & 干预措施
1
Other
Single Arm
干预措施: AMG 706 (Drug)
结局指标
主要结局
Safety (serious adverse events, adverse events, blood pressure and laboratory tests)
时间窗: Until objective evidence of disease progression, AMG 706 intolerance, or until loss of clinical benefit
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
不适用
An Open Label Treatment Extension Study of AMG706Subjects With Solid Tumors Previously Treated on a Seperate Amgen Protocol With AMG 706EUCTR2005-004323-18-DEAmgen Inc.
进行中（未招募）
1 期
An Open Label Treatment Extension Study of AMG706Subjects With Solid Tumors Previously Treated on a Seperate Amgen Protocol With AMG 706EUCTR2005-004323-18-GBAmgen Inc.64
进行中（未招募）
不适用
An Open Label Treatment Extension Study of AMG706EUCTR2005-004323-18-HUAmgen Inc.
进行中（未招募）
1 期
An Open Label Treatment Extension Study of AMG706Dependent on the previous Amgen protocol the patient has left.EUCTR2005-004323-18-DKAmgen Inc.160
进行中（未招募）
不适用
An Open Label Treatment Extension Study of AMG706Subjects With Solid Tumors Previously Treated on a Seperate Amgen Protocol With AMG 706EUCTR2005-004323-18-BEAmgen Inc.